Abstract
Metabolic hepatic steatosis (MASLD) and its possible progression to metabolic steatohepatitis (MASH) are a topic of public health importance as they have a high prevalence (estimated 30%) and unfavorable clinical outcomes, with mortality mainly related to cardiovascular events. GLP-1 receptor agonists have demonstrated a role in reducing biomarkers of these diseases. However, tirzepatide,…